NYSE:KDMN - Kadmon Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.60 -0.06 (-1.64 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$3.66
Today's Range$3.56 - $3.68
52-Week Range$2.05 - $5.86
Volume364,900 shs
Average Volume746,094 shs
Market Capitalization$290.75 million
P/E Ratio-2.58
Dividend YieldN/A
Beta3.97

About Kadmon (NYSE:KDMN)

Kadmon logoKadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.

Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:KDMN
CUSIPN/A
Phone212-308-6000

Debt

Debt-to-Equity RatioN/A
Current Ratio1.03
Quick Ratio1.02

Price-To-Earnings

Trailing P/E Ratio-2.58
Forward P/E Ratio-3.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.26 million
Price / Sales23.14
Cash FlowN/A
Price / CashN/A
Book Value($0.42) per share
Price / Book-8.57

Profitability

EPS (Most Recent Fiscal Year)($1.42)
Net Income$-79,770,000.00
Net Margins-1,159.00%
Return on EquityN/A
Return on Assets-115.90%

Miscellaneous

Employees101
Outstanding Shares78,790,000

Kadmon (NYSE:KDMN) Frequently Asked Questions

What is Kadmon's stock symbol?

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

How were Kadmon's earnings last quarter?

Kadmon Co. (NYSE:KDMN) issued its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The business had revenue of $0.43 million for the quarter, compared to analysts' expectations of $2.67 million. View Kadmon's Earnings History.

What price target have analysts set for KDMN?

4 brokerages have issued 12-month target prices for Kadmon's stock. Their forecasts range from $3.00 to $25.00. On average, they anticipate Kadmon's share price to reach $13.25 in the next year. View Analyst Ratings for Kadmon.

Who are some of Kadmon's key competitors?

Who are Kadmon's key executives?

Kadmon's management team includes the folowing people:
  • Dr. Harlan W. Waksal, Pres, CEO & Director (Age 65)
  • Mr. Konstantin Poukalov, Exec. VP & CFO (Age 34)
  • Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 50)
  • Mr. Charles Darder, Principal Accounting Officer & Controller
  • Dr. John L. Ryan M.D., Ph.D., Chief Medical Officer and Exec. VP (Age 75)

When did Kadmon IPO?

(KDMN) raised $101 million in an initial public offering (IPO) on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Has Kadmon been receiving favorable news coverage?

News stories about KDMN stock have trended somewhat positive on Friday, Accern reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kadmon earned a news sentiment score of 0.10 on Accern's scale. They also assigned press coverage about the company an impact score of 47.84 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Kadmon's major shareholders?

Kadmon's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Acuta Capital Partners LLC (7.55%), Millennium Management LLC (2.34%), BlackRock Inc. (1.96%), Sphera Funds Management LTD. (1.89%), Spark Investment Management LLC (0.47%) and Asymmetry Capital Management L.P. (0.25%). Company insiders that own Kadmon stock include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Institutional Ownership Trends for Kadmon.

Which major investors are buying Kadmon stock?

KDMN stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Acuta Capital Partners LLC, Sphera Funds Management LTD., Asymmetry Capital Management L.P., Sofinnova Ventures Inc, Tibra Equities Europe Ltd and Spark Investment Management LLC. Company insiders that have bought Kadmon stock in the last two years include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Insider Buying and Selling for Kadmon.

How do I buy shares of Kadmon?

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $3.60.

How big of a company is Kadmon?

Kadmon has a market capitalization of $290.75 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]


MarketBeat Community Rating for Kadmon (KDMN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kadmon (NYSE:KDMN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Kadmon in the last 12 months. Their average twelve-month price target is $13.25, suggesting that the stock has a possible upside of 268.06%. The high price target for KDMN is $25.00 and the low price target for KDMN is $3.00. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.502.402.25
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.25$13.25$11.40$9.75
Price Target Upside: 268.06% upside250.53% upside146.22% upside164.23% upside

Kadmon (NYSE:KDMN) Consensus Price Target History

Price Target History for Kadmon (NYSE:KDMN)

Kadmon (NYSE:KDMN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018HC WainwrightReiterated RatingBuy$25.00HighView Rating Details
2/13/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$7.00 ➝ $9.00HighView Rating Details
2/13/2018Jefferies GroupBoost Price TargetPositive ➝ Buy$16.00HighView Rating Details
10/9/2017WBB SecuritiesDowngradeHold ➝ Sell$3.00N/AView Rating Details
3/27/2017CitigroupLower Price TargetNeutral$6.00 ➝ $4.00HighView Rating Details
11/21/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Kadmon (NYSE:KDMN) Earnings History and Estimates Chart

Earnings by Quarter for Kadmon (NYSE:KDMN)

Kadmon (NYSE:KDMN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
2019 EPS Consensus Estimate: ($1.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.23)($0.23)($0.23)
Q2 20182($0.26)($0.26)($0.26)
Q3 20182($0.28)($0.25)($0.27)
Q4 20182($0.29)($0.22)($0.26)
Q1 20191($0.30)($0.30)($0.30)
Q2 20191($0.31)($0.31)($0.31)
Q3 20191($0.31)($0.31)($0.31)
Q4 20191($0.32)($0.32)($0.32)

Kadmon (NYSE KDMN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.2980)($0.27)$2.67 million$0.43 millionViewN/AView Earnings Details
3/6/2018Q4 2017($0.36)($0.24)$3.07 million$1.50 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.38)($0.42)$5.69 million$2.28 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.49)($0.44)$3.46 million$3.00 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.52)($0.39)$4.25 million$5.60 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.71)($0.50)$4.50 million$4.28 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($4.23)$3.90 million$5.70 millionViewN/AView Earnings Details
9/7/2016Q2 2016($0.88)($4.42)$6.48 million$6.42 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kadmon (NYSE:KDMN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kadmon (NYSE KDMN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.41%
Institutional Ownership Percentage: 64.07%
Insider Trading History for Kadmon (NYSE:KDMN)
Institutional Ownership by Quarter for Kadmon (NYSE:KDMN)

Kadmon (NYSE KDMN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/6/2017Goldentree Asset Management LpMajor ShareholderSell302,950$2.73$827,053.50View SEC Filing  
8/10/2017Harlan WaksalCEOBuy5,000$2.27$11,350.00110,747View SEC Filing  
8/8/2017Eugene BauerDirectorBuy5,000$2.36$11,800.001,716View SEC Filing  
8/8/2017Harlan WaksalCEOBuy3,707$2.34$8,674.38105,747View SEC Filing  
8/8/2017Steven N. GordonVPBuy1,000$2.47$2,470.00View SEC Filing  
7/31/2017Goldentree Asset Management LpMajor ShareholderSell349,661$2.60$909,118.60View SEC Filing  
7/11/2017Goldentree Asset Management LpMajor ShareholderSell34,462$3.69$127,164.78View SEC Filing  
6/29/2017Goldentree Asset Management LpMajor ShareholderSell64,375$4.04$260,075.00View SEC Filing  
6/27/2017Goldentree Asset Management LpMajor ShareholderSell108,827$3.69$401,571.63View SEC Filing  
6/26/2017Goldentree Asset Management LpMajor ShareholderSell515,643$3.51$1,809,906.93View SEC Filing  
6/22/2017Goldentree Asset Management LpMajor ShareholderSell767,363$3.50$2,685,770.50View SEC Filing  
3/13/2017Daniel S LoebMajor ShareholderBuy1,488,095$3.36$4,999,999.20View SEC Filing  
11/16/2016Harlan WaksalCEOBuy2,000$6.37$12,740.00102,040View SEC Filing  
11/14/2016Harlan WaksalCEOBuy2,000$6.79$13,580.00100,040View SEC Filing  
11/11/2016Konstantin PoukalovCFOBuy4,000$5.81$23,240.001,000View SEC Filing  
9/14/2016Daniel S LoebMajor ShareholderBuy19,611$7.79$152,769.69View SEC Filing  
9/13/2016Daniel S LoebMajor ShareholderBuy68,654$8.33$571,887.82View SEC Filing  
9/6/2016Daniel S LoebMajor ShareholderBuy81,781$9.39$767,923.59View SEC Filing  
8/26/2016Daniel S LoebMajor ShareholderBuy32,916$9.98$328,501.68View SEC Filing  
8/22/2016Daniel S LoebMajor ShareholderBuy11,305$10.00$113,050.00View SEC Filing  
8/15/2016Daniel S LoebMajor ShareholderBuy6,010$9.95$59,799.50View SEC Filing  
8/12/2016Daniel S LoebMajor ShareholderBuy87,529$9.98$873,539.42View SEC Filing  
8/5/2016Daniel S LoebMajor ShareholderBuy66,828$9.94$664,270.32View SEC Filing  
8/3/2016Daniel S LoebMajor ShareholderBuy1,431,996$11.35$16,253,154.60View SEC Filing  
8/1/2016Goldentree Asset Management LpMajor ShareholderBuy208,333$12.00$2,499,996.00View SEC Filing  
7/28/2016Bart M SchwartzDirectorBuy2,000$9.77$19,540.0026,211View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kadmon (NYSE KDMN) News Headlines

Source:
DateHeadline
MeiraGTx Aims For $86 Million US IPOMeiraGTx Aims For $86 Million US IPO
seekingalpha.com - May 18 at 4:32 PM
Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA CongressKadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress
finance.yahoo.com - May 17 at 9:46 AM
Kadmon (KDMN) Downgraded to Sell at Zacks Investment ResearchKadmon (KDMN) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 15 at 2:25 PM
Brokers Set Expectations for Kadmon Co.s Q2 2018 Earnings (KDMN)Brokers Set Expectations for Kadmon Co.'s Q2 2018 Earnings (KDMN)
www.americanbankingnews.com - May 14 at 2:18 AM
Kadmon Co. (KDMN) Given Consensus Recommendation of "Hold" by AnalystsKadmon Co. (KDMN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 13 at 7:39 PM
Kadmon Co. (KDMN) Expected to Post Quarterly Sales of $1.83 MillionKadmon Co. (KDMN) Expected to Post Quarterly Sales of $1.83 Million
www.americanbankingnews.com - May 13 at 2:54 AM
-$0.27 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter-$0.27 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter
www.americanbankingnews.com - May 11 at 5:38 PM
Equities Analysts Offer Predictions for Kadmon Co.s Q2 2018 Earnings (KDMN)Equities Analysts Offer Predictions for Kadmon Co.'s Q2 2018 Earnings (KDMN)
www.americanbankingnews.com - May 11 at 9:41 AM
Kadmon (KDMN) Announces Quarterly  Earnings Results, Beats Estimates By $0.03 EPSKadmon (KDMN) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - May 9 at 1:34 PM
BRIEF-Kadmon Reports First Quarter 2018 Financial ResultsBRIEF-Kadmon Reports First Quarter 2018 Financial Results
www.reuters.com - May 9 at 9:33 AM
Kadmon Provides Business Update and Reports First Quarter 2018 Financial ResultsKadmon Provides Business Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 4:25 PM
Kadmon (KDMN) Downgraded by Zacks Investment ResearchKadmon (KDMN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 5 at 1:50 AM
Kadmon (KDMN) Upgraded at ValuEngineKadmon (KDMN) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 1:31 PM
Kadmon (KDMN) Upgraded to "Buy" at Zacks Investment ResearchKadmon (KDMN) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 2 at 7:00 AM
Kadmon (KDMN) Lowered to Hold at Zacks Investment ResearchKadmon (KDMN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 28 at 7:40 AM
Kadmon (KDMN) Upgraded by Zacks Investment Research to BuyKadmon (KDMN) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 26 at 1:02 PM
$2.67 Million in Sales Expected for Kadmon Co. (KDMN) This Quarter$2.67 Million in Sales Expected for Kadmon Co. (KDMN) This Quarter
www.americanbankingnews.com - April 26 at 4:50 AM
Zacks: Analysts Expect Kadmon Co. (KDMN) to Announce -$0.25 Earnings Per ShareZacks: Analysts Expect Kadmon Co. (KDMN) to Announce -$0.25 Earnings Per Share
www.americanbankingnews.com - April 24 at 5:23 AM
Kadmon Co. (KDMN) Receives Consensus Recommendation of "Hold" from AnalystsKadmon Co. (KDMN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 7:24 PM
ValuEngine Lowers Kadmon (KDMN) to Strong SellValuEngine Lowers Kadmon (KDMN) to Strong Sell
www.americanbankingnews.com - April 14 at 8:35 PM
Piper Jaffray Analysts Give Kadmon (KDMN) a $7.00 Price TargetPiper Jaffray Analysts Give Kadmon (KDMN) a $7.00 Price Target
www.americanbankingnews.com - April 13 at 8:18 PM
Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host DiseaseKadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease
finance.yahoo.com - April 10 at 9:56 AM
Kadmon Co. (KDMN) Expected to Post Quarterly Sales of $3.28 MillionKadmon Co. (KDMN) Expected to Post Quarterly Sales of $3.28 Million
www.americanbankingnews.com - April 9 at 3:44 AM
-$0.25 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter-$0.25 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter
www.americanbankingnews.com - April 7 at 8:09 AM
Kadmon (KDMN) Stock Rating Lowered by Zacks Investment ResearchKadmon (KDMN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 28 at 3:48 PM
Kadmon Holdings Inc (KDMN) Given Consensus Rating of "Hold" by BrokeragesKadmon Holdings Inc (KDMN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 7:33 PM
Kadmon (KDMN) Rating Increased to Hold at Zacks Investment ResearchKadmon (KDMN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 10 at 5:09 PM
Kadmon (KDMN) Earns "Buy" Rating from HC WainwrightKadmon (KDMN) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - March 9 at 10:14 PM
Kadmon Holdings Inc Expected to Earn Q1 2018 Earnings of ($0.23) Per Share (KDMN)Kadmon Holdings Inc Expected to Earn Q1 2018 Earnings of ($0.23) Per Share (KDMN)
www.americanbankingnews.com - March 9 at 7:54 AM
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full ... - Business Wire (press release)Kadmon Reports Upcoming Milestones and Fourth Quarter and Full ... - Business Wire (press release)
www.businesswire.com - March 7 at 5:12 PM
Kadmon (KDMN) Releases  Earnings ResultsKadmon (KDMN) Releases Earnings Results
www.americanbankingnews.com - March 6 at 9:12 PM
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial ResultsKadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 6 at 4:46 PM
$3.72 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter$3.72 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter
www.americanbankingnews.com - March 6 at 8:58 AM
Kadmon Holdings Inc (KDMN) Expected to Post Earnings of -$0.34 Per ShareKadmon Holdings Inc (KDMN) Expected to Post Earnings of -$0.34 Per Share
www.americanbankingnews.com - March 4 at 3:14 AM
Kadmon Holdings Inc (KDMN) Receives Consensus Recommendation of "Hold" from BrokeragesKadmon Holdings Inc (KDMN) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 7:28 PM
Wired News – Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem MeetingsWired News – Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem Meetings
finance.yahoo.com - February 26 at 9:26 AM
Kadmon (KDMN) Reports Updated Positive Results from Phase 2 Study of KD025 in cGVHD - StreetInsider.comKadmon (KDMN) Reports Updated Positive Results from Phase 2 Study of KD025 in cGVHD - StreetInsider.com
www.streetinsider.com - February 25 at 5:06 PM
Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHDKadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD
finance.yahoo.com - February 23 at 9:27 AM
Kadmon (KDMN) PT Raised to $16.00 at Jefferies GroupKadmon (KDMN) PT Raised to $16.00 at Jefferies Group
www.americanbankingnews.com - February 18 at 8:10 PM
Kadmon Holdings Inc to Post FY2021 Earnings of ($2.83) Per Share, Jefferies Group Forecasts (KDMN)Kadmon Holdings Inc to Post FY2021 Earnings of ($2.83) Per Share, Jefferies Group Forecasts (KDMN)
www.americanbankingnews.com - February 15 at 4:10 PM
-$0.34 EPS Expected for Kadmon Holdings Inc (KDMN) This Quarter-$0.34 EPS Expected for Kadmon Holdings Inc (KDMN) This Quarter
www.americanbankingnews.com - February 15 at 11:10 AM
Kadmon (KDMN) Reports Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary FibrosisKadmon (KDMN) Reports Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis
www.streetinsider.com - February 14 at 9:07 AM
Why Molina Healthcare, Brighthouse Financial, and Kadmon Holdings Slumped TodayWhy Molina Healthcare, Brighthouse Financial, and Kadmon Holdings Slumped Today
finance.yahoo.com - February 14 at 9:07 AM
Why Karmon's "Positive" Data Turned Into a 21% DeclineWhy Karmon's "Positive" Data Turned Into a 21% Decline
finance.yahoo.com - February 14 at 9:07 AM
Vertex Pharmaceuticals, Kadmon Holdings Are Early Week Biotech MoversVertex Pharmaceuticals, Kadmon Holdings Are Early Week Biotech Movers
finance.yahoo.com - February 13 at 4:28 PM
Kadmon (KDMN) Receives "Positive" Rating from Piper Jaffray CompaniesKadmon (KDMN) Receives "Positive" Rating from Piper Jaffray Companies
www.americanbankingnews.com - February 13 at 11:12 AM
BRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary FibrosisBRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis
www.reuters.com - February 13 at 9:05 AM
After-Hours Stock Movers 02/12: (KDMN) (VIPS) (RNG) Higher; (HMNY) (AFMD) (moh) Lower (more...)After-Hours Stock Movers 02/12: (KDMN) (VIPS) (RNG) Higher; (HMNY) (AFMD) (moh) Lower (more...)
www.streetinsider.com - February 13 at 9:05 AM
Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPFKadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF
finance.yahoo.com - February 13 at 9:05 AM
Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary FibrosisKadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis
finance.yahoo.com - February 12 at 4:34 PM

SEC Filings

Kadmon (NYSE:KDMN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kadmon (NYSE:KDMN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kadmon (NYSE KDMN) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.